(Q42788454)

7 November 2017

title

Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections (English)

1 reference

7 November 2017

main subject

gram-positive bacteria

0 references

5

Jones RN

1 reference

7 November 2017

1

Pfaller MA

1 reference

7 November 2017

Rhomberg PR

2

1 reference

7 November 2017

Sader HS

series ordinal

3

1 reference

7 November 2017

Mendes RE

series ordinal

4

1 reference

7 November 2017

publication date

1 October 2010

1 reference

7 November 2017

published in

Journal of Chemotherapy

1 reference

7 November 2017

volume

22

1 reference

7 November 2017

issue

5

1 reference

7 November 2017

page(s)

304-311

1 reference

Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections

7 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Practice guidelines for the diagnosis and management of skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

A prospective study of outcomes, healthcare resource utilization, and costs associated with postoperative nosocomial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Economic burden of surgical site infections at a European university hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Genotypic characteristics of Staphylococcus aureus isolates from a multinational trial of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Emergence of community-associated methicillin-resistant Staphylococcus aureus infection among patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

The efficacy and safety of ceftobiprole in the treatment of complicated skin and skin structure infections: evidence from 2 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Epidemiological and resistance issues in multidrug-resistant staphylococci and enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Clinical impact of antibiotic-resistant Gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

In vitro activity of telavancin against resistant gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Telavancin: a novel lipoglycopeptide for serious gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Response to emerging infection leading to outbreak of linezolid-resistant enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Postantibiotic effects of telavancin against 16 gram-positive organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

Comparative efficacies of telavancin and vancomycin in preventing device-associated colonization and infection by Staphylococcus aureus in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.5.304

10.1179/JOC.2010.22.5.304

21 January 2018

Identifiers

DOI

1 reference

7 November 2017

1 reference